An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy

Inclusion Criteria:

1. Patients aged 18-70 years (inclusive) with chronic HBV infection prior to baseline;

2. Subjects who have received a entecavir or tenofovir ester treatment for more than 1year before screening ;

3. HBsAg > 250 IU/mL and HBV DNA < 60 IU/mL at screening period;

4. ALT≤ 2×ULN;

5. Participants must have understood and signed the ICF.

Exclusion Criteria:

1. Confirmed co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV);

2. History of liver disease other than chronic hepatitis B;

3. History of Gilbert's Disease;

4. History of decompensated liver disease or any sign of decompensated liver disease atthe screening period;

5. Evidence of moderate or severe fibrosis or cirrhosis;

6. Evidence of HCC or AFP > 50 ng/ml at the screening period.

7. Any Clinical laboratory values meet the certain standards at the screening period;

8. Subjects have clinically significant, uncontrolled heart disease and/or recent cardiacevent;

9. Risks of serious kidney and respiratory diseases;

10. Impaired gastrointestinal (GI) function or GI disease that may alter absorption ofQL-007 as determined by the Investigator;

11. Receiving medications that meet one of the following criteria and that cannot bediscontinued ≥1 week prior to the start of treatment QL-007:

• Medication with a known risk of prolonging the QT interval or inducing Torsadesde Pointes;

• Moderate or strong inhibitors or strong inducers of CYP3A4

12. Intake of any drugs that can reduce enzyme activity;

13. History of bleeding diathesis;

14. Risks of mental and nervous system diseases during screening;

15. Pregnant or lactating female subjects; Female subjects of childbearing age who werenot willing to use effective contraception throughout the study period or malesubjects whose partners were fertile but were not willing to use effectivecontraception;

16. Volunteers who took an Investigational Product within 3 months or who have been within 5 half-lives of other trial drugs before the randomization;

17. Any other condition , which in the opinion of investigator would make a patient unfitfor participation in a clinical study.